The results from this proof of concept study should be further evaluated in large cohorts that involve all stages of retinoblastoma patients, using a fully validated assay to further improve the accuracy of detecting low‐level RB1 mutation in plasma DNA. This evidence concerns the gene RB1 and retinoblastoma.